Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by PoorOpinionon Jan 19, 2018 5:23pm
130 Views
Post# 27397967

RE:RE:RE:RE:RE:RE:Anybody considered the rough ride CINODS had?

RE:RE:RE:RE:RE:RE:Anybody considered the rough ride CINODS had?But the problem is "superficial thought processes" do occur at all levels. Here's an example. I worked at a biotech that had an antibody based product going thru the approval process. Things were generally fine until one day a completely unrelated company, with a completely unrelated antibody, to a completely unrelated target, in a completely unrelated medicinal field, injected six health volenteers and got an enormous cytokine storm response. Massive swelling, necrotized tissue, disfigurement, amputations, near death, the lot.
The response turned out to be very specific to that drug but when the alarm bells went off at the regulators the superficial response was to lump our drug in with that drug and make a whole new set of demands on us. You could argue it was a reasonable safety response but it was also very unsophisticated.

Its reasonable to think the hangover from naproxcinod still exists, I'm arguing in favour of stupidity I know. If these trial results dont turn out to be the tipping point we expect them to be its worth considering why. If they do then who cares we're all rich!

I got something out of this exchange though. I have held ATE so long that I tend to just look at new developments on thier own merits. It good to have a reference back to some possible concerns  others might have and look at what Antibe have been doing in light of that.

Bullboard Posts